Yüklüyor......
In vivo targeting of B-cell lymphoma with glycan ligands of CD22
Antibody-mediated cell depletion therapy has proven to provide significant clinical benefit in treatment of lymphomas and leukemias, driving the development of improved therapies with novel mechanisms of cell killing. A current clinical target for B-cell lymphoma is CD22, a B-cell–specific member of...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2010
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2890185/ https://ncbi.nlm.nih.gov/pubmed/20181615 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-12-257386 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|